Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 17.5%

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 470,700 shares, a growth of 17.5% from the November 15th total of 400,700 shares. Based on an average daily trading volume, of 159,400 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Immix Biopharma stock. Invst LLC bought a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 27,000 shares of the company's stock, valued at approximately $57,000. Invst LLC owned 0.10% of Immix Biopharma at the end of the most recent quarter. 11.26% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Immix Biopharma Stock Performance

NASDAQ IMMX traded down $0.09 on Monday, hitting $1.95. 193,875 shares of the stock were exchanged, compared to its average volume of 184,692. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $7.75. The firm has a market capitalization of $53.64 million, a P/E ratio of -2.29 and a beta of 0.28. The stock has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $1.93.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). Sell-side analysts expect that Immix Biopharma will post -0.64 earnings per share for the current fiscal year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.